GlassScriptPhysician profile
Uma Edupuganti
NPI 1548455918
$6,338.28
in general payments reported to CMS, 2019-2025
32 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $227 · 2022: $64.31 · 2023: $4,270 · 2024: $255 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,020 · Travel and Lodging: $1,462 · Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,020.00 |
| Travel and Lodging | $1,461.77 |
| Food and Beverage | $803.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,528.51 | 2022-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $300.80 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $297.52 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $163.00 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.63 | 2019-2025 | Jascayd, Ofev |
| Genentech USA, INC. | $114.79 | 2019-2024 | Xolair |
| Amgen INC. | $70.04 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $68.61 | 2019-2024 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $68.38 | 2019-2020 | |
| Csl Behring | $60.22 | 2023-2024 | Kcentra |
| Pfizer INC. | $51.36 | 2019 | |
| Electromed, INC. | $48.47 | 2019 | |
| Insmed, INC. | $40.72 | 2023-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $40.09 | 2023 | |
| Merck Sharp & Dohme LLC | $38.53 | 2020-2025 | Zerbaxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $29.97 | 2019-2020 | |
| Grifols USA, LLC | $28.31 | 2020-2023 | Prolastin-C Liquid |
| Avadel Cns Pharmaceuticals, LLC | $27.09 | 2024 | Lumryz |
| United Therapeutics Corporation | $23.32 | 2019-2020 | |
| Axsome Therapeutics, INC. | $21.07 | 2023 | Sunosi |
| Alnylam Pharmaceuticals INC. | $20.99 | 2023 | Onpattro |
| Ani Pharmaceuticals, INC. | $20.64 | 2022 | |
| Zoll Respicardia, INC. | $20.04 | 2023 | Remede System |
| Astellas Pharma US INC | $19.13 | 2019 | |
| Philips North America LLC | $18.33 | 2023 | |
| Siemens Medical Solutions USA, INC. | $16.66 | 2024 | Cios Spin |
| Verona Pharma, INC. | $16.46 | 2025 | Ohtuvayre |
| Abbvie INC. | $15.02 | 2024 | |
| Lilly USA, LLC | $13.49 | 2025 | Zepbound |
| Mylan Specialty L.P. | $13.00 | 2019 | |
| Allergan, INC. | $12.80 | 2020 | |
| Breas Medical, INC. | $10.29 | 2025 | Vivo 45 Ls, Vivo 1/2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Edupuganti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.